Enamel Matrix Derivative and Demineralized Freeze-Dried Bone Allograft in treatment of Class II furcation defect

Comparative Evaluation of Enamel Matrix Derivative and Demineralized Freeze-Dried Bone Allograft in the treatment of Class II furcation defects - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056791

Enrollment

Registered

2023-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Enamel Matrix Derivative: Extra oral antisepsis and intra oral antisepsis will be performed with 5% povidone iodine solution and 0.2% chlorhexidine digluconate mouth rinse respectively.

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing for voluntary participation & have signed informed consent for the described procedure. Systemically healthy patients (ASA I & II) with Periodontitis Class II buccal furcation defects of horizontal component more than 3mm on clinical & radiographic evaluation The sites should exhibit clinical evidence of PPD of more than 3mm and CAL of more than 2mm Patients with established willingness and ability to perform adequate oral hygiene

Exclusion criteria

Exclusion criteria: 1.Subjects who have received periodontal flap/regenerative therapy within the past 1 year Patients who have received antibiotic therapy within the past six months Pregnant and lactating patients Smokers and tobacco chewers Patients who demonstrate poor oral hygiene maintenance after Phase I therapy Tooth with gingival recession exposing furcation, endodontic-pulpal involvement, or mobility > Grade II Systemic illness known to affect the outcomes of periodontal therapy; such as uncontrolled diabetes mellitus, cardiac diseases, immune-compromised (e.g., HIV individuals, under radiotherapy), patients taking medications such as corticosteroids or calcium channel blockers, which are known to interfere with periodontal wound healing Patients with any known allergy to drugs

Design outcomes

Primary

Measure	Time frame
The possible outcome of this study will be to see the improvement in Clinical Attachment Level and Bone forming capacity using Enamel Matrix Derivative in furcation defectsTimepoint: Baseline 3 Months 6 Months	—

Secondary

Measure	Time frame
To assess gingival inflammationTimepoint: Baseline 3 Months 6 Months	—

Countries

India

Contacts

Public ContactRia Sahay

Sardar Patel Post Graduate Institute of Dental and Medical Sciences

docamitabh74@gmail.com9415085343

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026